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Abstract     30 
Topic:  To compare the accuracy of Optical Coherence Tomography (OCT) with alternative 31 
tests for monitoring neovascular age-related macular degeneration (nAMD) and detecting 32 
disease activity among eyes previously treated for this condition 33 
Clinical Relevance:  Traditionally FFA has been considered the reference standard to 34 
detect nAMD activity but FFA is costly and invasive.  Replacement of FFA by OCT can be 35 
justified if there is a substantial agreement between tests.        36 
Methods: Systematic review and meta-analysis.  Index test: OCT.  Comparator tests: visual 37 
acuity, clinical evaluation (slit lamp), Amsler chart, colour fundus photographs, infra-red 38 
reflectance, red-free images/blue reflectance, fundus autofluorescence imaging (FAF), 39 
indocyanine green angiography (ICGA), preferential hyperacuity perimetry (PHP) and 40 
microperimetry.  We searched the following databases: MEDLINE, MEDLINE In Process, 41 
EMBASE, Biosis, SCI, the Cochrane Library, DARE, MEDION and HTA database, last 42 
literature search: March 2013.   We used QUADAS-2 to assess risk of bias.   43 
Results:  We included eight studies involving over 400 participants.  Seven reported the 44 
performance of OCT (three TD-OCT, three SD-OCT, one both types) and one the 45 
performance of ICGA in the detection of nAMD activity.  We did not find studies directly 46 
comparing tests in the same population.  The pooled sensitivity and specificity (95% CI) of 47 
TD-OCT and SD-OCT for detecting active nAMD was 85% (72% to 93%) and 48% (30% to 48 
67%), respectively.  One study reported ICGA, with sensitivity of 75.9% and specificity of 49 
88.0% for the detection of active nAMD.   Half of the studies were considered to have high 50 
risk of bias.  51 
Conclusions:   There is a substantial disagreement between OCT and FFA findings in 52 
detecting active disease in patients with nAMD who are being monitored. Both modalities 53 
may be needed to comprehensively monitor patients with nAMD.  54 
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Introduction 55 
Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment 56 
of neovascular age-related macular degeneration (nAMD).  Visual outcomes following anti-57 
VEGF therapy1-4 have been unparalleled by previous therapies which included laser 58 
photocoagulation5-6 and photodynamic therapy.7 The effectiveness of anti-VEGF drugs 59 
depends, however, on frequent monitoring and early diagnosis of reactivation of the 60 
condition.  “Fundus fluorescein angiography (FFA) interpreted by an ophthalmologist was in 61 
the recent past the reference standard for the detection of active nAMD among those eyes 62 
already treated8,9 as it directly detects the presence of the active neovascularisation.  63 
However, FFA is an invasive and a time-consuming test with, although rare, potentially 64 
serious side effects.  Other alternative monitoring technologies are available of which the 65 
most widely used is optical coherence tomography (OCT).“ 66 
OCT, including time-domain (TD-OCT) and the most recently developed spectral-domain 67 
(SD-OCT), is a light-wave based technology that allows the imaging of the retina and 68 
choroid, obtaining “sections” through areas with neovascularisation and surrounding tissues.  69 
Scan rates and resolution parameters have greatly improved over the last decade and 70 
continue to develop.  OCT is a non-invasive, non-contact test typically undertaken by trained 71 
medical photographers or technicians and interpreted by ophthalmologists.  If OCT were to 72 
be able to accurately detect the re-activation of nAMD then FFA would not be needed. 73 
The aim of this study was to evaluate the accuracy, interpretability and acceptability 74 
of OCT alone or in combination with other tests compared with clinical evaluation of FFA for 75 
the detection of active disease in patients with nAMD under treatment and surveillance.   76 
 77 
 78 
 79 
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Methods 80 
The target condition was nAMD of any phenotype.  Eligible participants were individuals who 81 
had been previously treated for nAMD with any type of treatment, and who were monitored 82 
to detect active disease.   Thus, patients could have active or stable neovascular disease 83 
“The index test was OCT, alone or in combination with other tests, i.e., we included studies 84 
that used OCT alone or associated with other test or tests to detect nAMD disease activity, 85 
including any of the following: clinical evaluation with slit lamp biomicroscopy, visual acuity, 86 
Amsler grid, colour fundus photography, infra-red reflectance, red-free images, fundus 87 
autofluorescence imaging (FAF), indocyanine green angiography (ICGA), preferential 88 
hyperacuity perimetry (PHP) and microperimetry.  The reference standard was FFA.  89 
Participants were individuals with known, treated nAMD, with any type of treatment, and who 90 
were monitored for the condition to detect active disease.  We considered direct (head-to-91 
head) comparisons in which all participants received the index test, comparator test(s) and 92 
the reference standard; indirect comparisons (e.g. case control studies) in which estimates 93 
of the accuracy of the respective tests were obtained in different study groups, and 94 
randomised controlled trials evaluating effectiveness outcomes where e.g. treatment was 95 
based on OCT compared with FFA findings. We also included studies evaluating the 96 
acceptability and/or interpretability of the tests.  97 
We identified published, unpublished and ongoing studies from searches of electronic 98 
databases (from 1995 to March 2013) and appropriate websites. There were no language 99 
restrictions. We searched MEDLINE, MEDLINE In-Process, EMBASE, Biosis and Science 100 
Citation Index (SCI) for all reviews.  We searched the Cochrane Central Register of 101 
Controlled Trials (CENTRAL) for additional reports of RCTs reporting effectiveness 102 
outcomes and PsycINFO and ASSIA for studies reporting acceptability data.  The Cochrane 103 
database of Systematic Reviews (CDSR), Database of Abstracts of reviews of Effects 104 
(DARE), MEDION and HTA database were searched for relevant systematic reviews and 105 
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HTA reports.  We searched abstracts and presentations from recent conferences (from 106 
January 2009 to September 2012) of the Academy of Ophthalmology (AAO), the Association 107 
for Research in Vision and Ophthalmology (ARVO), and the European Association for Vision 108 
and Eye Research (EVER) and also the WHO International Clinical Trials Registry Platform 109 
(ICTRP), Clinical Trials.gov and EU Clinical Trials Register for ongoing studies. Websites of 110 
key journals, professional organisations and manufacturers of equipment were also 111 
consulted.  We also evaluated reference lists of all included studies for possible inclusion 112 
and we contacted authors for details of additional potentially relevant reports.  113 
Two reviewers independently screened the titles and abstracts (if available) of all reports 114 
identified by electronic searches.  We obtained full-text copies of all potentially relevant 115 
papers and two reviewers independently assessed them for inclusion.  Two reviewers 116 
independently assessed the risk of bias and applicability concerns of included full-text 117 
studies, using an adapted version of the updated quality assessment of diagnostic accuracy 118 
studies (QUADAS-2) checklist.10 The QUADAS-2 checklist is designed to be adapted to the 119 
specific review topic.   The investigators resolved disagreements by consensus or arbitration 120 
by a third reviewer.  QUADAS-2 consists of four key domains covering (1) patient selection, 121 
(2) index test, (3) reference standard, and (4) flow of patients through the study and timing of 122 
the index test(s) and reference standard.  Each domain is assessed in terms of the risk of 123 
bias.  The first three domains are also assessed for concerns regarding their applicability in 124 
terms of whether (i) the participants and setting, (ii) index test, its conduct or interpretation 125 
and (iii) target condition as defined by the reference standard match the question being 126 
addressed by the review.  Within each domain signaling questions are included to assist in 127 
making a judgment about the risk of bias, with the standard tool containing 11 such 128 
questions across the four domains.  129 
QUADAS-2 was designed to be adaptable to a specific review topic.  For this review, 130 
QUADAS-2 was modified by adding an additional signaling question to domain 1 (patient 131 
selection) to assess whether participant pre-selection had been avoided.  Domains 2 (index 132 
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test), 3 (reference standard) and 4 (flow and timing) were retained in their entirety.  133 
Therefore the modified tool contained 12 signaling questions, with each worded so that a 134 
rating of ‘Yes’ was always optimal in terms of methodological quality.  If any signaling 135 
questions within a domain were rated ‘No’ then that domain was judged to be at high risk of 136 
bias.  With regard to question 9 in the modified tool (appropriateness of the time interval 137 
between the index test and the reference standard), it was agreed that to be considered 138 
appropriate, the time interval between the index test and reference standard should be no 139 
longer than one week.”   140 
Regarding the statistical analysis we calculated sensitivity and specificity of individual 141 
studies when possible.   Where two or more studies reported sufficient data we planned to 142 
create summary receiver operating characteristic (SROC) curves.   We intended to fit meta-143 
analysis models using the hierarchical summary receiver operating characteristic (HSROC) 144 
model11 with the SAS software (version 9.1) when possible.   We used a symmetric SROC 145 
model, as it allows estimation of random effects for the threshold and accuracy effects 146 
accounting for the active and non-active sample sizes in each study.   We arranged to 147 
produce the SROC curves from the HSROC models on the corresponding SROC plots.  We 148 
planned to report a point estimate and 95% confidence interval (CI) for each model for the 149 
summary sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds 150 
ratios (DORs).  151 
 152 
Results 153 
We identified 4682 titles and abstracts, of which 179 reports were evaluated in full-text 154 
(Figure 1).  Eight12,13,14,15,16,17,18,19 were monitoring studies involving people previously 155 
diagnosed with nAMD and under follow-up surveillance; one study, by Salinas-Alaman et 156 
al.,17 reported results for both diagnosis and monitoring (Table 1).   No studies evaluated the 157 
performance of OCT associated with other test(s).   158 
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Of the eight included studies, four were prospective,15,16,17,19 three were retrospective12,13,14 159 
while in the study by van de Moere et al.18 this information was not reported.  In five studies 160 
the participants were a consecutive sample.13,14,16,17,19 The eight studies enrolled 463 161 
participants.   162 
Four studies were judged to be high risk of bias for reasons such as inappropriate exclusions 163 
and pre-selection of participants, length of time between the index test and the reference 164 
standard, and not all participants being included in the analysis (Figure 2). All of the 165 
monitoring studies were judged to be applicable to our study question.     166 
Some studies reported the “eye “as the unit of analysis, i.e., only data of a single 167 
examination/comparison of an eye at one point in time was included in the study.  Other 168 
studies reported an “examination” as the unit of analysis, i.e., a patient or eye was examined 169 
several times over a period of time, and the authors included data of several examinations of 170 
the same patient and eye.  Of the seven studies reporting OCT, five used the eye as the unit 171 
of analysis (number of eyes analysed = 363);12,13,14,18,19  in four of these one eye per patient 172 
was analysed (n = 304 eyes).13,14,18,19 Two studies reported examination as the unit of 173 
analysis (both TD-OCT).15,17  Two studies reported detection of classic and occult CNV;14 174 
pigment epithelial detachment (PED) and cystoid macular oedema.18 The studies by 175 
Henschel et al.15 and van de Moere et al.18 also reported the performance of OCT in 176 
detecting intraretinal and subretinal fluid.  177 
In two studies12,14 the participants had received anti-vascular endothelial growth factor (anti-178 
VEGF) therapy while in five13,15,17,18,19 the treatment was photodynamic therapy (PDT).  In the 179 
study reporting ICGA16 the participants had received laser photocoagulation.   180 
The median (range) prevalence of active nAMD across five studies where this information 181 
was available at participant level was 57.9% (49.2% to 83.3%).12,13,14,18,19  182 
Three TD-OCT studies12,13,19 and two SD-OCT reports,12,14 with the eye as the unit of 183 
analysis, reported both sensitivity and specificity, providing sufficient data for inclusion in a 184 
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meta-analysis.  Figure 3 shows forest plots of the sensitivity and specificity of the individual 185 
studies and SROC curves for (a) all OCT studies, (b) the three TD-OCT studies and (c) the 186 
two SD-OCT studies, respectively.  Table 2 shows the pooled estimates for these studies.  187 
For all OCT studies, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) 188 
and 48% (30% to 67%) respectively.  For TD-OCT, the pooled sensitivity and specificity 189 
(95% CI) was 70% (56% to 80%) and 65% (48% to 79%).  For TD-OCT and the group of all 190 
four OCT studies the likelihood ratio and DOR values reported were below the level 191 
suggestive of strong evidence.  It was not possible to calculate pooled estimates for the two 192 
SD-OCT studies due to insufficient data.  These studies reported sensitivities of 94%14  and 193 
90%12 and specificities of 27%14 and 47%,12 which suggests that SD-OCT has higher 194 
sensitivity than TD-OCT but lower specificity.   195 
Two studies used examination as the unit of analysis.  Henschel et al.,15 in an analysis of 61 196 
pairs of TD-OCT and FFA examinations from 14 patients, reported sensitivity of 96.8% and 197 
specificity of 36.7% for CNV based on detection of intraretinal and/or subretinal fluid.  198 
Salinas-Alaman et al.,17 in an analysis of 176 pairs of TD-OCT and FFA examinations 199 
(number of patients not stated), reported sensitivity of 95.7% and specificity of 59.0% based 200 
on detection of intraretinal or subretinal fluid. 201 
Four studies12,14,15,18 reported the sensitivity of OCT in detecting active nAMD phenotypes or 202 
active nAMD based on detection of intraretinal/subretinal fluid (see Table 3).  The study by 203 
Giani et al.14 reported high sensitivity for the detection by SD-OCT of both classic and occult 204 
CNV activity (90.9% and 100% respectively).  In the studies by Henschel et al.15 (unit of 205 
analysis: examination) and van de Moere et al.18 (unit of analysis: eye) sensitivity was higher 206 
for nAMD activity based on detection of intraretinal fluid (90.3% and 82.9% respectively) 207 
compared with subretinal fluid (71.0% and 47.1% respectively).  Van de Moere et al.18 also 208 
reported sensitivity of TD-OCT for detection of cystoid macular oedema and pigment 209 
epithelial detachment, both low at 22.9% and 5.7% respectively.  In the study by Khurana et 210 
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al12 the sensitivity of SD-OCT was higher than that of TD-OCT for nAMD activity based on 211 
the detection of intraretinal fluid, retinal cystoid abnormalities or subretinal fluid.     212 
One study, by Khurana et al.,12 compared TD-OCT with SD-OCT in an analysis of 59 eyes of 213 
56 participants.  Although sensitivity was considerably higher for SD-OCT than for TD-OCT 214 
(89.7% versus 58.6%), specificity was lower (46.7% versus 63.3%). 215 
One study, by Regillo et al.,16 in an analysis of 54 pairs of indocyanine green angiograms 216 
compared with fluorescein angiograms, obtained from 24 eyes of 21 patients, reported 217 
sensitivity of 75.9% and specificity of 88.0% in detecting nAMD activity.   218 
No studies were identified that met our inclusion criteria providing information on clinical 219 
effectiveness outcomes (e.g. visual acuity) when treatment was based on OCT compared 220 
with FFA findings.  Only one monitoring study, by van de Moere et al.,18  reported 221 
information relating to the interpretability of the tests.  This TD-OCT study reported that, of 222 
136 participants enrolled, 17 (12.5%) were excluded from the analysis due to the poor 223 
quality of the OCT or FFA images.  The study did not specify how many of these poor quality 224 
images were OCT images and how many were FFA.  No studies were identified that met our 225 
inclusion criteria reporting the acceptability of the tests, either to those providing the tests or 226 
to those receiving them. 227 
 228 
Discussion 229 
Due to the burden of nAMD to patients and health care providers, an effective and efficient 230 
monitoring strategy to detect active disease is needed.   The use of frequent (monthly or 231 
two-monthly) FFA is not recommended.  FFA is hampered by its cost, the fact that it is a 232 
relatively time-consuming invasive imaging technology and, although rare, possible risks.  233 
Current Preferred Practice Patters by the AAO advise the use of FFA”depending on the 234 
clinical findings and judgement of the treating ophthalmologist”.9  OCT is now routinely used 235 
for monitoring eyes with nAMD previously treated.   236 
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We identified a relatively small body of evidence comparing OCT against a reference 237 
standard of FFA for the diagnosis of active nAMD in patients under surveillance and treated 238 
for this condition.   We included eight monitoring studies (all full-text) involving over 400 239 
participants.  Seven reported the performance of OCT (five TD-OCT, one SD-OCT, one both 240 
types) and one the performance of ICGA in the detection of nAMD activity.    241 
To compare the performance of diagnostic tests ideally direct comparisons of the accuracy 242 
of different tests applied to the same population would be most informative.   Alternatively it 243 
is possible to evaluate studies of different tests applied to different populations against a 244 
common reference standard, using models to indirectly compare tests.  In this review four of 245 
the OCT studies provided sufficient data for inclusion in a meta-analysis.  The pooled 246 
sensitivity (95% CI) for all OCT was moderately high at 85% (72% to 93%) but with low 247 
specificity at 48% (30% to 67%).  For TD-OCT, the pooled sensitivity and specificity was 248 
moderate at 70% (56% to 80%) and 65% (48% to 79%) respectively.  It was not possible to 249 
calculate pooled estimates for the two SD-OCT studies using hierarchical summary receiver 250 
operating characteristic (HSROC) methodology due to insufficient data.  These studies 251 
reported sensitivities of 94%14 and 90%12 and specificities of 27% 14 and 47%.12  Other than 252 
OCT, one study reported ICGA, with sensitivity of 75.9% and specificity of 88.0% for the 253 
detection of active nAMD.   We did not find other studies reporting the performance of 254 
alternative technologies.   255 
This study suggests that SD-OCT may be more sensitive but less specific in detecting active 256 
nAMD than TD-OCT.  It is likely that SD-OCT can detect small amounts of fluid in the retina 257 
(due to its high resolution) better than TD-OCT.  However, fluid does not always indicate 258 
active CNV but may indicate RPE malfunctioning, for instance related to RPE atrophy, which 259 
has now been recognised to occur frequently in eyes with nAMD undergoing anti-VEGF 260 
therapies.2, 3, 20, 21 Some of the observed heterogeneity among studies results can be 261 
explained by the different populations, phenotypes, proportion of active cases, type of 262 
treatment, and methodological quality. 263 
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In terms of strengths of this study, a comprehensive literature search was undertaken and 264 
both English and non-English language studies were included.  We assessed risk of bias 265 
using a modified version of the QUADAS-2 questionnaire, tailored to the needs of this 266 
review.   We used a robust method, HSROC model, for the analysis, which takes account of 267 
the trade-off between true/false positives and models between-study heterogeneity.22 268 
The reference standard test used for this review was FFA interpreted by an ophthalmologist, 269 
and therefore was assumed to have perfect sensitivity and specificity.  Consequently it was 270 
not possible to address the question of whether OCT might actually be a better test than 271 
FFA and have higher sensitivity or specificity than the current reference standard.  One 272 
approach that has been suggested for determining when a new test should replace the 273 
reference standard is that proposed by Glasziou et al.23  Glasziou et al. suggested the use of 274 
a third, ‘fair umpire’ test, which although potentially less accurate than either the new test or 275 
the reference standard, could be considered nonetheless a fair umpire test if its errors were 276 
independent of the other tests.23 However, the authors acknowledged that this would usually 277 
be difficult to demonstrate.  Unfortunately, none of the included OCT studies involving a third 278 
test provided a sufficient level of detail to allow us to explore this approach.    279 
The false positive rate of OCT was high.  A few studies suggested possible explanations for 280 
their false positive results.  Subretinal or intraretinal fluid, readily detected by OCT, 281 
especially by SD-OCT, may not necessarily indicate active neovascular AMD and may be 282 
seen over disciform scars and even atrophic areas.24  If the diagnosis of active nAMD is 283 
established by the presence of fluid on OCT false positives could, thus, be made, leading to 284 
unnecessary treatments.  Similar lack of agreement between OCT and FFA to diagnose 285 
nAMD in high risk eyes have been observed by Do et al.25     286 
The clinical implications of this review are potentially important as we found evidence of 287 
substantial lack of agreement between OCT and FFA to determine activity of nAMD lesions.   288 
There are also potential implications regarding the interpretation of results of landmark 289 
studies that have used only OCT to guide decisions to treat nAMD, such as the prn arms of 290 
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the CATT study2 and the HARBOR study.26  It is possible the differences in efficacy between 291 
monthly and prn arms might be explained in part by a sub-optimal of diagnostic accuracy of 292 
OCT to detect active nAMD. 293 
In conclusion, our review identified a relatively small number of studies, of variable quality, 294 
on the performance of OCT in the monitoring of people with treated nAMD under 295 
surveillance to detect disease activity.  The available evidence suggests that although OCT 296 
is a sensitive test for detecting reactivation of nAMD, it has poor specificity. Consequently, it 297 
is not recommended that OCT is used alone to detect reactivation of nAMD in patients under 298 
surveillance. According to current evidence OCT should not replace the reference standard 299 
of FFA for monitoring patients with nAMD.    300 
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Figure 1. Flow diagram outlining the screening and selection process of articles 393 
 394 
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